Preliminary evidence of the presence of lymphatic vessels immunoreactive for D2-40 and Prox-1 in human pterygium

Oncology Reports

Volumn 26, Issue 5, 2011, Pages 1111-1113

  Cimpean, Anca Maria ^a   Sava, Mihai Poenaru ^a   Raica, Marius ^a   Ribatti, Domenico ^b  

^a VICTOR BABES UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BARI MEDICAL SCHOOL   (Italy)

Author keywords

D2 40; Ki 67; Lymphangiogenesis; Lymphatic vessels; Prox 1; Pterygium

Indexed keywords

MONOCLONAL ANTIBODY D2-40; MONOCLONAL ANTIBODY KI 67; PROTEIN ANTIBODY; PROX 1 ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH FLOW; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; MICROVASCULATURE; PRIORITY JOURNAL; PTERYGIUM;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; CONJUNCTIVA; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC VESSELS; MALE; PTERYGIUM; TUMOR SUPPRESSOR PROTEINS;

EID: 80053161002     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1342     Document Type: Article

References (25)

1. Peckar CO: The aetiology and histo-pathogenesis of pterygium. A review of the literature and a hypothesis. Doc Ophthalmol 31: 141-157, 1972.
2. Vaughan D and Ashbury T: Conjunctiva. In: General Ophthalmology. Vaughan D and Ashbury T (eds). Lange Medical Publications, Los Altos, p82, 1977.
3. Crǎiţoiu S, Ciprian L, Rodica M, et al: Etiopathogenic aspects in development and evolution of pterigyum. Oftalmologia 52: 29-34, 2008 (In Romanian).
4. Duke-Elder S: Conjunctival diseases. Degenerations. In: System of Ophthalmology. Duke-Elder S (ed). Henry Kimpton, London, pp573-582, 1974.
5. Džunic B, Jovanović P, Veselinović D, et al: Analysis of patho-histological characteristics of pterygium. Bosn J Basic Med Sci 10: 307-313, 2010.
6. Pérez-Rico C, Pascual G, Sotomayor S, et al: Tropoelastin and fibulin overexpression in the subepithelial connective tissue of human pterygium. Am J Ophthalmol 151: 44-52, 2011.
7. Detorakis ET, Zaravinos A and Spandidos DA: Growth factor expression in ophthalmic pterygia and normal conjunctiva. Int J Mol Med 25: 513-516, 2010.
8. Seifert P and Sekundo W: Capillaries in the epithelium of pterygium. Br J Ophthalmol 82: 77-81, 1998.
9. Marcovich AL, Morad Y, Sandbank J, et al: Angiogenesis in pterygium: morphometric and immunohistochemical study. Curr Eye Res 25: 17-22, 2002.
10. Aspiotis M, Tsanou E, Gorezis S, et al: Angiogenesis in pterygium: study of microvessel density, vascular endothelial growth factor, and thrombospondin-1. Eye 21: 1095-1101, 2007.
11. Kria L, Ohira A and Amemiya T: Immunohistochemical locali-zation of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem 98: 195-201, 1996.
12. Lee DH, Cho HJ, Kim JT, et al: Expression of vascular endo-thelial growth factor and inducible nitric oxide synthase in pterygia. Cornea 20: 738-742, 2001.
13. Di Girolamo N, Kumar RK, Coroneo MT, et al: UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells. Invest Ophthalmol Vis Sci 43: 3430-3437, 2002.
14. Di Girolamo N, Wakefield D and Coroneo MT: UVB-mediated induction of cytokines and growth factors in pterygium epithelial cells involves cell surface receptors and intracellular signaling. Invest Ophthalmol Vis Sci 47: 2430-2437, 2006.
15. Ribatti D, Nico B, Maxia C, et al: Neovascularization and mast cells with tryptase activity increase simultaneously in human pterygium. J Cell Mol Med 11: 585-589, 2007.
16. Ribatti D, Nico B, Perra MT, et al: Correlation between NGF/TrkA and microvascular density in human pterygium. Int J Exp Pathol 90: 615-620, 2009.
17. Esquenazi S: Treatment of early pterygium recurrence with topical administration of interferon alpha. Can J Ophthalmol 40: 185-187, 2005.
18. Hosseini H, Najabat M and Khalili MR: Bevacizumab (Avastin) as a potential adjunct in the management of pterygia. Med Hypotheses 69: 925-927, 2007.
19. Bahar I, Kaiserman I, McAllum P, et al: Subconjunctival beva-cizumab injection for corneal neovascularization in recurrent pterygium. Curr Eye Res 33: 23-28, 2008.
20. Banifatemi M, Razeghinejad MR, Hosseini H, et al: Bevacizumab and ocular wound healing after primary pterygium excision. J Ocul Pharmacol Ther 27: 17-21, 2011.
21. Fallah Tafti MR, Khosravifard K, Mohammadpour M, et al: Efficacy of intralesional bevacizumab injection in decreasing pterygium size. Cornea 30: 127-129, 2011.
22. Bock F, Onderka J, Dietrich T, et al: Bevacizumab as a potent inhibitor of inflammatory corneal angiogenesis and lymphangio-genesis. Invest Ophthalmol Vis Sci 48: 2545-2552, 2007.
23. Lee JW, Park WY, Kim TI, et al: Clinical results after application of bevacizumab in recurrent pterygium. J Korean Ophthalmol Soc 49: 1901-1909, 2008.
24. Seifert P, Eckert J and Spitznas M: Topological-histological investigation of the pterygium. Graefes Arch Clin Exp Ophthalmol 239: 288-293, 2001.
25. Hill JC and Maske R: Pathogenesis of pterygium. Eye 13: 218-226, 1989.